AIT
AIT engaged in developing a new therapeutic molecules and diagnostic reagents for a wide range of cancer and viral diseases, based on a novel platform technology of generating T-Cell Receptor-Like (TCRL) human recombinant antibodies mimicking the natural immune surveillance system.